Author(s):
Pinheiro, Hugo 
; Carvalho, Joana ; Oliveira, Patrícia ; Ferreira, Daniel ; Teixeira Pinto, Marta ; Osório, Hugo ; Licastro, Danilo ; Bordeira-Carriço, Renata ; Jordan, Peter ; Lazarevic, Dejan ; Sanges, Remo ; Stupka, Elia ; Huntsman, David ; Seruca, Raquel ; Oliveira, Carla
Date: 2012
Persistent ID: http://hdl.handle.net/10400.18/919
Origin: Repositório Científico do Instituto Nacional de Saúde
Subject(s): Vias de Transdução de Sinal e Patologias Associadas; e-cadherin; Gastric Cancer; Transcription
Description
Disruption of E-cadherin (CDH1 gene) expression, subcellular localization or function arises during initiation and progression of almost 90% of all epithelial carcinomas. Nevertheless, the mechanisms through which this occurs are largely unknown. Previous studies showed the importance of CDH1 intron 2 sequences for proper gene and protein expression, supporting these as E-cadherin cis-modulators. Through RACE and RT-PCR, we searched for transcription events arising from CDH1 intron 2 and discovered several new transcripts. One, named CDH1a, with high expression in spleen and absent from normal stomach, was demonstrated to be translated into a novel isoform, differing from canonical E-cadherin in its N-terminal, as determined by mass-spectrometry. Quantitative and functional assays showed that when overexpressed in an E-cadherin negative context, CDH1a replaced canonical protein interactions and functions. However, when co-expressed with canonical E-cadherin, CDH1a increased cell invasion and angiogenesis. Further, interferon-induced genes IFITM1 and IFI27 levels were increased upon CDH1a overexpression. Effects on invasion and IFITM1 and IFI27 expression were reverted upon CDH1a specific knockdown. Importantly, CDH1a was de novo expressed in gastric cancer cell lines. This study presents a new mechanism by which E-cadherin functions are impaired by cis-regulatory mechanisms possibly with the involvement of inflammatory machinery. If confirmed in other cancer models, our data encloses potential for designing targeted therapies to rescue E-cadherin function.
